58 results on '"Fruchart, Jean Charles"'
Search Results
2. Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
3. Combination Lipid Therapy in Type 2 Diabetes
4. Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity
5. The Nuclear Receptor Rev-erbα Is a Liver X Receptor (LXR) Target Gene Driving a Negative Feedback Loop on Select LXR-Induced Pathways in Human Macrophages
6. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
7. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome
8. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome
9. The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity
10. Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women?
11. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
12. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
13. Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of β-oxidation
14. Impact of Atorvastatin on Cardiovascular Risk in Patients with Metabolic Syndrome and CHD: The Treating to New Targets (TNT) Study: 619-P
15. Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets
16. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study
17. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial
18. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis
19. Apolipoprotein E Knockout Mice Over-Expressing Human Tissue Inhibitor of Metalloproteinase 1 Are Protected against Aneurysm Formation but Not against Atherosclerotic Plaque Development
20. PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a
21. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment
22. Therapeutic Roles of Peroxisome Proliferator–Activated Receptor Agonists
23. Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis
24. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
25. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
26. Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis
27. The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α
28. Glucose Regulates the Expression of the Farnesoid X Receptor in Liver
29. Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function
30. Liver X receptors: new players in atherogenesis?
31. Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor α Gene via Activation of the Farnesoid X Receptor
32. HDL and triglyceride as therapeutic targets
33. Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation
34. Increased ABCA1 activity protects against atherosclerosis
35. DNA Binding-Independent Induction of IκBα Gene Transcription by PPARα
36. Characterization of the Human PPARα Promoter: Identification of a Functional Nuclear Receptor Response Element
37. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element
38. PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism
39. PPAR-α-Null Mice Are Protected From High-Fat Diet-Induced Insulin Resistance
40. An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
41. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice
42. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
43. Circadian and Glucocorticoid Regulation of Rev-erbα Expression in Liver*
44. A Truncated Human Peroxisome Proliferator-Activated Receptor α Splice Variant with Dominant Negative Activity
45. Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
46. Fibrates Increase Human REV-ERBα Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element
47. Retinoids Increase Human Apo C-III Expression at the Transcriptional Level via the Retinoid X Receptor: Contribution to the Hypertriglyceridemic Action of Retinoids
48. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators
49. Postprandial Dyslipidemia: A Risk Factor for Coronary Heart Disease
50. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.